TY - CHAP
T1 - CHAPTER 1: Genome-wide Discovery of MicroRNA Biomarkers for Cancer Precision Medicine
AU - Zhu, Zhongxu
AU - Han, Guiyuan
AU - Huang, Hao
AU - He, Lingli
AU - Chen, Yu
AU - Ke, Jia
AU - Gao, Feng
AU - Vermeulen, Louis
AU - Wang, Xin
N1 - Publisher Copyright: © The Royal Society of Chemistry 2021.
PY - 2021
Y1 - 2021
N2 - MicroRNAs (miRNAs) are an abundant class of small non-coding RNA molecules that regulate gene expression at the post-transcriptional level. MiRNAs are found frequently dysregulated during cancer initiation, development, and metastasis, and are present in a wide variety of clinical specimens such as blood, saliva, urine, and feces. These relatively abundant and stable molecules provide great potential to be exploited for cancer detection, prognosis, and therapy response prediction, as well as disease monitoring. Herein, we introduce state-of-the-art development of miRNA biomarkers with a particular focus on a genome-wide, data-driven methodology, which has demonstrated higher robustness and reproducibility compared to traditional methods. We will first review miRNA-based biomarkers for various clinical applications and discuss the potential limitations of traditional approaches. Next, we will summarize the major steps involved in a data-driven methodology for biomarker development. Finally, we will discuss the main advantages and challenges in real clinical applications, as well as possible solutions and emerging opportunities.
AB - MicroRNAs (miRNAs) are an abundant class of small non-coding RNA molecules that regulate gene expression at the post-transcriptional level. MiRNAs are found frequently dysregulated during cancer initiation, development, and metastasis, and are present in a wide variety of clinical specimens such as blood, saliva, urine, and feces. These relatively abundant and stable molecules provide great potential to be exploited for cancer detection, prognosis, and therapy response prediction, as well as disease monitoring. Herein, we introduce state-of-the-art development of miRNA biomarkers with a particular focus on a genome-wide, data-driven methodology, which has demonstrated higher robustness and reproducibility compared to traditional methods. We will first review miRNA-based biomarkers for various clinical applications and discuss the potential limitations of traditional approaches. Next, we will summarize the major steps involved in a data-driven methodology for biomarker development. Finally, we will discuss the main advantages and challenges in real clinical applications, as well as possible solutions and emerging opportunities.
UR - http://www.scopus.com/inward/record.url?scp=85098672307&partnerID=8YFLogxK
U2 - https://doi.org/10.1039/9781788019958-00001
DO - https://doi.org/10.1039/9781788019958-00001
M3 - Chapter
VL - 2021-January
T3 - RSC Detection Science
SP - 1
EP - 34
BT - Detection Methods in Precision Medicine
A2 - Yang, Mengsu
A2 - Thompson, Michael
PB - Royal Society of Chemistry
ER -